LogicBio Announces Presentation of Retrospective Study of Di

LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalonic Acidemia


LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalonic Acidemia
- Data presented at ACMG meeting evaluate disease progression in non-transplanted patients and children receiving liver transplantation
News provided by
Share this article
Share this article
LEXINGTON, Mass., May 3, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced results from a retrospective study of the disease course in pediatric patients living with severe methylmalonic acidemia (MMA) caused by a deficiency of the mitochondrial enzyme methylmalonyl-CoA mutase (MMUT). The study results were recently highlighted in a poster presentation at the American College of Medical Genetic and Genomics (ACMG) Annual Clinical Genetics Meeting.

Related Keywords

, Daniel Gruskin , Bill Berry , Berry Company Public Relations , Gilmartin Group , American College Of Medical Genetic , Logicbio Therapeutics Inc , Nasdaq , Logicbio Therapeutics , American College , Medical Genetic , Annual Clinical Genetics , Methylmalonic Acidemia , Bio Therapeutics , ர சி து பெர்ரி , பெர்ரி நிறுவனம் பொது உறவுகள் , கில்மார்டின் குழு , நாஸ்டாக் , அமெரிக்கன் கல்லூரி , ஆண்டு மருத்துவ ஜெநெடிக்ஸ் , உயிர் சிகிச்சை ,

© 2025 Vimarsana